Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates

FDA has released a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA, for the treatment of psychiatric and substance abuse disorders.

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

At a recent House Energy and Commerce Health Subcommittee hearing titled “Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development,” lawmakers examined ways to increase efficiency and speed across early-stage clinical trial development.

July 17, 2026

Vol.52 No.28

By Claire Marie Porter

In Brief

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

LSU Health New Orleans received a five-year, $3.1 million NIH grant to support pancreatic cancer research led by investigators in the LSU LCMC Health Cancer Center.

July 17, 2026

Vol.52 No.28

Clinical Roundup

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer have reported that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

July 17, 2026

Vol.52 No.28

Drugs & Targets

FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility

FDA approved Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer, regardless of cisplatin eligibility.

July 17, 2026

Vol.52 No.28

Drugs & Targets

FDA approves Revtorpyk for HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer

FDA approved Revtorpyk (gedatolisib) for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Revtorpyk is the only inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to receive FDA approval.

July 17, 2026

Vol.52 No.28

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

YOU MAY BE INTERESTED IN

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility

FDA approves Revtorpyk for HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

YOU MAY BE INTERESTED IN

FDA final guidance on psychedelics opens the door to psycho-oncology researchGuidance permits treatment without psychotherapy, alarming scientists, advocates

House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role

LSU LCMC Health cancer center researchers receive $3.1M NIH grant to study pancreatic cancer

Experimental KRAS vaccine generates immune response against pancreatic cancer in people at high risk, phase I study finds

FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility

FDA approves Revtorpyk for HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer

Never miss an issue!

Login

FDA final guidance on psychedelics opens the door to psycho-oncology research
Guidance permits treatment without psychotherapy, alarming scientists, advocates